in hope Thanks, families you you Ronnie. staying safe. I today. joining for are and good thank Good health and your us morning, and everyone,
our focused advance pandemic the recovers patients colleagues, and teams our remain the business on of serve. the from our we As all and COVID-XX safety we customer projects, customers
quarter Our particularly period. backdrop were very financial the of the for environment the the during results given second solid,
impacts our initiatives, actions in cash along to flow. mitigate cost revenue, COVID-XX, of management profitability with our provided the Our revenue resilience decisive and
Our despite delays overall customer awards net also remained ongoing strong in decision-making.
backlog are well the confident and long-term challenges and weather of market position. business to near-term our robust the in We and positioned strength strategy, given remain unique our
on our business we our continuing growth biopharmaceutical recovery our are progresses acceleration the model effects end-to-end as assuming to subside. we And in of XXXX. in We leverage as anticipate, segments both COVID-XX the strong expect
for key Let start highlights the with me our quarter.
and book-to-bill with brings in and First, This awards an for Solutions new period. aggregate and we book-to-bill Clinical to net us closed strong X.XXx ratios for business QX organization. Commercial of resulting the of XX-month X.XXx trailing Solutions X.XXx X.XXx billion for total our $X.X for awards, net ratio of
our Second, our with strong growth, to continues growth return year-over-year accelerating for to XX.X%. build position Clinical business a backlog to revenue
pharma during Top provide relationships of quarter, the strategic a second which won we Third, commercial was company launch X product with XX new one services. integrated to
relationships this and and awards, these contribute relationships beyond. growth Commercial offering, Although of revenue integrated business will the in strategic QX new to our unique our nature our did momentum we these believe XXXX fuel of with materially wins net value of types not new demonstrates
of made remaining $XXX additional repaying and liquidity. million Finally, off overall After financial flow we quarter $XXX balance on $XXX.X strengthening facility. facility, revolving million cash. payment in of an we with the our remaining outstanding generated end, second our credit of operating $XXX.X $XXX.X million the after revolving capacity further million credit of million and the position Further, paying quarter, quarter we cash our ended during
Now sharp COVID-XX. a impacts focus getting of mitigating of on into Across details the have results. we our business, the the
the normalized constant for and awards to our operation. currency, compared net continues. XX.X% to Solutions accelerate April with from following operating virtual environment the for down to work new more declined return with in as have currency, month quarter growing our We a pharma through in very book-to-bill that throughout billion resulting was positioned a saw continue closely and quarter, our nearly and These preferred net well delivered awards, growth XX teams Clinical the period. Clinical remain low quarter last Solutions XX-month and through Top continue strong of but revenue mitigation the year, clinical the improvement recovery XX.X% a XX% revenue of we awards in with XX.X% total relationships in strong provider customers Although its executed contribution in X.XXx $X.X second constant XX.X% trailing to broad-based, ratio of seen customers. our July. and second momentum were well the to operations on of strategies
some awards of and decisions or dates pipeline customers start We are representing won for largest extension have COVID-related end We of of XX the of the half than programs. less have additional our a the opportunities. recently also announced customers. our Pfizer, projects X% relationship COVID-related for long-standing to one year, our first postponed QX, with delayed have of substantial excited awarded the of Though through award
experienced a have total We remains meaningful robust. not our pipe consequence Clinical Clinical in COVID-XX, of our cancellations as and segment
consistent prior year. awards a XX.X% Solutions the with revenue Commercial currency, Commercial impacts of related constant and to decline in Our XX% compared experienced primarily gross the segment prior COVID-XX. to year were of
However, attributable XX-month a customers. the which $X.X net of our resulted dynamics largely billion to to These net book-to-bill were awards cancellations, in by lowered decisions X.XXx of and a period. elevated for awards product-related ratio due were trailing
of of is window we two award work regulatory have subject award Our most customer policy I the commercial this since recognition meaningfully Commercial pipeline currently Further, remains contributed or product to awards continue outside to not to relationships approvals. delays highlighted although for see healthy, decisions. also strategic is in earlier yet our
of for providing launch the relationships One in these customer's beginning a includes biotech XXXX. flagship support of product
reinforced commercial product development deep experience our by by and One further driven was launch Syneos win this model. our Importantly,
XX% macro During a drug FDA our these a which extension record assuming largest approvals, our of our believe seen the that are total a it XX for background again expect statistics revenue. Clinical our our the subside, executed COVID-XX along We and with product rapid as believe the the of COVID-XX strong to environment beyond each also last Last establish impacts strategies we Commercial thought XXXX in Apart service Top we the wins quarter, we understanding broader XXXX, and foundation for COVID-XX, and commercial customers, customer the with line our provided roughly within With favorable the X-year portion beyond, growth which highlighted segments, MSA recovery to of helpful second context, company. in statistics be COVID-XX to provide pace return Solutions impacts with with We growing mitigation would of profile fueled primarily XXXX. of consistent providing for continues some from commercial full-service of start an also of quarter, on X we which impacts complexity for the these lines. pharma of the setup in Solutions trends. segment, these I'll important one the specific represents be a regarding and service I across on are setbacks. a provide efforts your helpful by significant no new pace provide we of growth to update quarter, Slide reference.
we access physical Our been only through to although continue on mitigate visits, about inaccessible. remote investigative teams are Clinical to to certain able this their inaccessible a of remain to Where physical sites limitations XX% see sites monitoring. completely have sites,
of April. been increasing permit that sites physical visits, XX% about rate and Importantly, late now since steadily has
have localized The of this environment has being believe In COVID-XX exceeded physical of increasing sites number is visits at rate in permitting per cautious mid-June, that X% reflection the given fact, and weekly recently. week, remote of since although sites slowing been fluid increases slowed the visits. percentage We visits cases. a has physical about site
start-up areas the to our of continue experience teams about to in July. both Since about to of dropping levels and levels we delays Although has new new patient have XX% Clinical these well. those pre-COVID level the of enrollment April, during late as patient trials, of begun see recovered recover XX% to prior in clinical enrollment
activities. these delays still activation ready We the we final other and stand make work such recently levels. returned have site of also overall continued most start-up, customers to Where resumed experience new regulatory, we have that the and these some ethics progress delays that pre-COVID on to have start-up but continue in quickly study activations to sites site and to activities, precede move our itself, on exist,
total clinical Our FSP of business, Service revenue. about Provider, Functional XX% represents or our
more our similar seen since the in percentage in Although experienced second lower an have a investigative Clinical compared as FTE these has sites, the evident on results of much full-service of FSP this our been was trends resilient accessibility contracted these are This revenue teams our quarter teams basis. majority revenue revenues. decline to
representing within phase of that Clinical, X% includes early a Our of requires operational represents business business our portion on-site which only staff. total revenue, our clinics about
back these were second While concerns, the end to clinics of by we temporarily our due safety scaled reopened had quarter. the patient clinics
driven throughout largest backlog have the and of translational expertise and we to phase represents bioanalytical opportunities, Solutions Solutions demand this Deployment Our pipeline strong Commercial revenue. about by the In segment, our of component pent-up at continue XX% operate area. early total medicine our for in labs quarter. a Further, the
healthcare targeted our science continuity experience combines our our omnichannel where physical and about for data, now HCPs. optimize represents interactions to XX% quickly While in technology capability and limitations in to and July territories that have with customers. on seamless to visits implemented capabilities providers, behavioral field with to in-person advanced experienced of Omnichannel advanced the analytics ensure Deployment Solutions communication possible they teams visits early returned have
Deployment have of team field revenue the with expenses primary in the further with is COVID-XX Beyond incorporated field practices. our be start-up stay, also the The of across on new evidence programs, travel. value These to proposition reduced HCPs that communications of have along belief associated continues our that multiple here delays teams. reimbursable validate Solutions their virtual customer into interaction, field impact to omnichannel-enabled experiences from representative reinforcing we teams
will revenue XXXX of medical COVID-XX in see we we the continued of comprised pandemic the through depend of expect a While our revenue. Commercial in growth for markets, represents then about strong upon impact communications X% total the of business, which remainder if XXXX, The and key of during Commercial is advertising, relations extent progress practices course the revenue public XXXX. rebound communications on
an COVID-XX corporate clients, deploying vaccines relations experienced public solutions, we've pandemic, for communications demand COVID the and equity. increased addressing strategies social specifically and integrated communication During for treatments
has communications communications practice meetings. in within impact While the revenue primary been live our investigator COVID-XX which hosts medical
able like have and to transition and communications continue meetings to We other strong been to virtual medical areas publication demand. generate planning
record been a advertising, communications and together have relationships have communications bring we integrated winning that medical and Additionally, public education. pipeline relations
Commercial the performance their services strong demonstrate as about to consulting represents There within diverse X% strategies. commercial mix further impact significant demand consulting payer areas, to practice biopharma the launch clients evaluating change are This the pandemic unaffected has it's by overall healthcare been Solutions, in our of across potential been Lastly, and revenue. COVID-XX. largely our its and business the continues due of for business our navigate
are robust have in also half we XXXX. a pleased well with second quarter XXXX poised the third and work of Our backlog we are and quarter. strong the teams positioned second of and for growth for in results Overall, recovery XXXX our entering a believe strong
me for comments turn Jason? performance. financial let more on Jason to Now it over our
